Continuous positive airway pressure may be a preferred alternative to noninvasive ventilation as first-line therapy in stable ambulatory patients with obesity hypoventilation syndrome and concurrent severe obstructive sleep apnea.
Wakix is a selective H3 receptor antagonist/inverse agonist and the first treatment for narcolepsy that is not scheduled as a controlled substance.
The FDA has rejected the supplemental New Drug Application for Hetlioz (tasimelteon; Vanda Pharmaceuticals) for the treatment of jet lag disorder.
Among patients with early Parkinson disease, impulse control behaviors are common in the early stages of the disease, with a significant proportion having symptoms of subsyndromal impulse control disorders.
Although the long-term effects of melatonin in school-aged children are unknown, its use is common in this population, according to the findings of a recently published cross-sectional study.
Continuous positive airway pressure treatment reduces depression symptoms in patients with coexisting obstructive sleep apnea and cardiovascular disease.
De facto medical use of cannabis for symptom relief is common among adult-use dispensary customers in Colorado.
In this single-center, prospective, cross-sectional cohort study, the authors aimed to compare the efficacy of zolpidem to melatonin in the treatment of hospital-related insomnia.
The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; Jazz Pharmaceuticals) a Schedule IV controlled substance.
Smoking may be related to the severity of obstructive sleep apnea.
